Selected article for: "antiretroviral therapy and non progressor status"

Author: Dyer, Wayne B; Zaunders, John J; Yuan, Fang Fang; Wang, Bin; Learmont, Jennifer C; Geczy, Andrew F; Saksena, Nitin K; McPhee, Dale A; Gorry, Paul R; Sullivan, John S
Title: Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection
  • Document date: 2008_12_11
  • ID: 0ddutmdd_4
    Snippet: A cohort of blood product recipients with transfusionacquired HIV (TAHIV) infected between 1981 and 1984 was followed prospectively by the Australian Red Cross Blood Service HIV Lookback Team since 1987. There are individuals in this cohort who have remained asymptomatic for 27 years since infection without antiretroviral therapy; some maintaining plasma HIV RNA levels to below detectable levels and a stable CD4 T cell count, thus retaining elite.....
    Document: A cohort of blood product recipients with transfusionacquired HIV (TAHIV) infected between 1981 and 1984 was followed prospectively by the Australian Red Cross Blood Service HIV Lookback Team since 1987. There are individuals in this cohort who have remained asymptomatic for 27 years since infection without antiretroviral therapy; some maintaining plasma HIV RNA levels to below detectable levels and a stable CD4 T cell count, thus retaining elite non-progressor status. Early natural history studies on this and other cohorts suggested that TAHIV infection may result in a shorter time to AIDS than sexually-acquired (SA) HIV infection [1, 2] . This observed increase in the rate of disease progression in TAHIV may be due to the higher inoculation volume of blood product compared with the much smaller blood or genital fluid exchange involved in SAHIV infection [1] , as well as the known immunomodulatory effect of transfusion on immune function [3, 4] . Age is also an independent predictor for an increased rate of HIV disease progression [5, 6] . The bias toward an aged population requiring transfusion is part of the composite disadvantage of transfusion as a route of HIV infection [1] . In addition to HIV infection, survival may be influenced by the underlying medical cause for transfusion. Yet despite these disadvantages, we previously observed a high frequency of nonprogression in this TAHIV cohort after 20 years of infection [7] .

    Search related documents:
    Co phrase search for related documents
    • aged population and high frequency: 1
    • aged population and immune function: 1, 2
    • aged population and increase rate: 1, 2, 3, 4, 5, 6, 7
    • aged population and independent predictor: 1, 2, 3
    • aged population and medical cause: 1
    • aged population and observed increase: 1, 2, 3
    • aged population and prospectively follow: 1
    • aged population and short time: 1, 2
    • AIDS short time and short time: 1
    • antiretroviral therapy and cell count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
    • antiretroviral therapy and detectable level: 1
    • antiretroviral therapy and disease progression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • antiretroviral therapy and high frequency: 1
    • antiretroviral therapy and HIV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • antiretroviral therapy and immune function: 1, 2, 3, 4
    • antiretroviral therapy and increase rate: 1
    • antiretroviral therapy and natural history: 1, 2, 3, 4
    • antiretroviral therapy and non progressor status: 1
    • antiretroviral therapy and observed increase: 1